GlaxoSmithKline logoMaking a difference every day - Sustainability in Environment, Helath and Safety Report 2003
Corporate Responsibility Report 2003Download this Report
  EHS Home
  About this Report
  Scope
  Executive Statements
  Framework
  Vision and policies
  Planning
  Organisation
  Management Systems
  Programmes
  Audit
  Stakeholder Communication
  Reward and Recognition
  Issues
  Performance
  Verification Statement
  Global Reporting Initiative Content Index
  Index
   

 

Hazard Assessment and Communication

Business Processes
Hazard Assessment and Communication
Environmental Programmes
EHS Programmes in GlaxoSmithKline Commercial
Ergonomics
Occupational Hygiene and Control of Chemical Agents
Work Related Mental Illness
Human Immunodeficiency Virus (HIV)
Process Safety and Safety Engineering

GlaxoSmithKline assesses environment, health and safety (EHS) hazards associated with the research, development and manufacture of our products in order to meet ethical and regulatory requirements and to ensure the workplace is safe and the environment unharmed.

Hazard Testing
In 2003, we gave priority and applied significant efforts to identify gaps in core EHS hazard information for materials used in existing processes. This included information related to flammability, dust explosivity, possible adverse health effects, occupational hygiene analytical methods and environmental fate and effects. The number of tests conducted and the sample throughput at our testing facility increased by over 88%. Data gaps for most priority GlaxoSmithKline materials were closed.

Our in-house hazard determination laboratory (HDL) conducts tests for flammability and dust explosivity properties of materials handled within research & development and manufacturing facilities. A new test, Sustained Combustibility, was added to the list of studies currently available from the HDL. This test enables us to provide flammability data for GlaxoSmithKline products enabling more accurate classification of these products for transportation. This new addition ensures that we meet current regulations for transport and in some cases it provides a cost saving when the handling requirements for the known hazards are not as costly as the handling requirements for unknown hazards.

We continued to refine and use innovative in-house testing and a sequential, tiered approach to assess occupational health hazards for GlaxoSmithKline materials. This approach rapidly identifies indicators of potential hazard for chemicals at early stages of product development and reduces the number of animals required for each assessment. Extensive environmental hazard information was developed for existing materials and these data will be extremely useful to assess potential environmental impacts of GlaxoSmithKline products and processes.

Efforts in 2004 will focus on new pharmaceuticals in research & development and supporting European manufacturing processes affected by the implementation of the EU regulations applicable to explosive atmospheres (Directive 99/92/EC, ATEX 137).

Occupational and Environmental Exposure Limits
GlaxoSmithKline develops occupational and environmental exposure limits for our materials in order to guide the design and selection of chemical control systems to protect our employees' health and the environment. During 2003, our experts established new occupational exposure limits for fifty materials and completed innovative approaches for the rapid development of data-driven environmental limits.

Distribution of EHS Hazard Information on GlaxoSmithKline Materials
GlaxoSmithKline uses a global intranet system called MSDS@gsk to provide EHS hazard information in a unified format to all operations. This system provides material safety data sheets (MSDS) and related information for GlaxoSmithKline materials and products and for key manufacturing and process chemicals. The information, available in English, French, German, Italian, Portuguese and Spanish, is updated regularly with new information available to the company worldwide by the day after the update. In 2003 the MSDS data integration project was completed which saw over 4,000 documents from the heritage companies converted to the GlaxoSmithKline format or archived. Of these, over 1,000 are now available throughout the company as MSDS for GlaxoSmithKline pharmaceutical and consumer healthcare products sold in a number of key markets worldwide . For US-marketed products, the approximately 300 MSDS are also available on an external website for direct access by external customers.

 
Previous

Next